Evidence map›Paper›PMID 40140348›Full record

ArticleBlood cancer journal2025

Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development.

Pralay Mukhopadhyay, Hesham A Abdullah, Joanna B Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Pralay MukhopadhyayGSK, Upper Providence, PA, USA.
Hesham A AbdullahGSK, Upper Providence, PA, USA.
Joanna B OpalinskaGSK, Upper Providence, PA, USA.
Prani PakaGSK, Upper Providence, PA, USA.
Eric RichardsGSK, Upper Providence, PA, USA.
Katja WeiselUniversity Medical Center of Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0001-9422-6614
Suzanne TrudelPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Maria-Victoria MateosUniversity Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain.ORCID http://orcid.org/0000-0003-2390-1218
Meletios Athanasios DimopoulosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.ORCID http://orcid.org/0000-0001-8990-3254
Sagar LonialWinship Cancer Institute, Emory University Hospital, Atlanta, GA, USA. sloni01@emory.edu.ORCID http://orcid.org/0000-0002-8322-9323

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40140348
PMCPMC11947437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.